PMID- 15899774
OWN - NLM
STAT- MEDLINE
DCOM- 20050713
LR  - 20131121
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 123
IP  - 6
DP  - 2005 Jun
TI  - Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute 
      promyelocytic leukemia.
PG  - 840-8
AB  - We describe 17 cases of therapy-related acute promyelocytic leukemia (tAPL). 
      Treatment for the initial neoplasms (mostly carcinomas and non-Hodgkin lymphomas) 
      included radiation and chemotherapy in 11 patients, radiation in 3, and 
      chemotherapy in 3. The interval between the initial neoplasm and tAPL ranged from 
      17 to 166 months (median, 40 months). Morphologically, all 13 cases with 
      available bone marrow aspirate smears showed tAPL. Dyserythropoiesis or 
      dysmegakaryopoiesis was identified in 11 cases. In 2 cases, too few nonneoplastic 
      cells and, in all cases, too few maturing granulocytes were present to assess for 
      dysplasia. Conventional cytogenetics or fluorescence in situ hybridization (FISH) 
      showed the t(15;17)(q22;q21) in all cases; 6 as a sole abnormality, 9 with 
      additional abnormalities, and 2 assessed only by FISH. Reverse 
      transcription-polymerase chain reaction (PCR) studies showed PML/RARa in 13 cases 
      (8 short form, 5 long form). Mutations of the flt3 gene were detected by PCR in 5 
      (42%) of 12 cases. We conclude that dysplastic features, secondary cytogenetic 
      abnormalities, and flt3 mutations are common in tAPL.
FAU - Yin, C Cameron
AU  - Yin CC
AD  - Department of Hematopathology, The University of Texas M.D. Anderson Cancer 
      Center, Houston, USA.
FAU - Glassman, Armand B
AU  - Glassman AB
FAU - Lin, Pei
AU  - Lin P
FAU - Valbuena, Jose R
AU  - Valbuena JR
FAU - Jones, Dan
AU  - Jones D
FAU - Luthra, Rajyalakshmi
AU  - Luthra R
FAU - Medeiros, L Jeffrey
AU  - Medeiros LJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 5688UTC01R (Tretinoin)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Bone Marrow/pathology
MH  - Chromosome Aberrations
MH  - Female
MH  - Flow Cytometry
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Promyelocytic, Acute/drug therapy/*genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Neoplasms, Second Primary/*genetics/*pathology
MH  - Oncogene Proteins, Fusion/genetics
MH  - Proto-Oncogene Proteins/genetics
MH  - Receptor Protein-Tyrosine Kinases/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tretinoin/therapeutic use
MH  - fms-Like Tyrosine Kinase 3
EDAT- 2005/05/19 09:00
MHDA- 2005/07/14 09:00
CRDT- 2005/05/19 09:00
PHST- 2005/05/19 09:00 [pubmed]
PHST- 2005/07/14 09:00 [medline]
PHST- 2005/05/19 09:00 [entrez]
AID - TJFFK819RPCLFKJ0 [pii]
AID - 10.1309/TJFF-K819-RPCL-FKJ0 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2005 Jun;123(6):840-8. doi: 10.1309/TJFF-K819-RPCL-FKJ0.